faculty photo

Richard Aplenc, MD, PhD, MSCE

Professor of Pediatrics (Oncology) at the Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
Colket Translational Research Building
Suite 4060
3501 Civic Center Blvd
Philadelphia, PA 19104
Office: 267-426-7252
A.B. (Classics)
Princeton University, 1988.

University of Pennsylvania, Post-Baccalaureate Pre-Health Program, 1989.
University of Virginia, 1994.
MSCE (Clinical Epidemiology and Biostatistics)
University of Pennsylvania, 2002.
PhD (Epidemiology)
University of Pennsylvania, 2011.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Cao L, Huang Y, Getz KD, Seif AE, Ruiz J, Miller TP, Fisher BT, Aplenc R, Li Y: Applying machine learning to identify pediatric patients with newly diagnosed acute lymphoblastic leukemia using administrative data. Pediatr Blood Cancer 71(3), Mar 2024 Notes: doi: 10.1002/pbc.30858.

Ruiz J, Li Y, Cao L, Huang YV, Tam V, Griffis HM, Winestone LE, Fisher BT, Alonzo TA, Wang YJ, Dang AT, Kolb EA, Glanz K, Getz KD, Aplenc R, Seif AE: Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia. Cancer 130(6): 962-972, Mar 2024 Notes: doi: 10.1002/cncr.35109.

Ruiz J, Kelly RK, Aplenc R, Laetsch TW, Seif AE: Absolute Neutrophil Count Clinical Trial Eligibility Criteria for Pediatric Oncology Phase I and Phase I/II Trials by Sponsorship. Pediatr Blood Cancer Feb 2024 Notes: doi: 10.1002/pbc.30925.

Abla O, Ries RE, Triche Jr TJ, Gerbing RB, Hirsch B, Raimondi S, Cooper TM, Farrar JE, Buteyn N, Harmon LM, Wen H, Deshpande AJ, Kolb EA, Gamis AS, Aplenc R, Alonzo T, Meshinchi S: Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia. Blood Adv Feb 2024 Notes: doi: 10.1182/bloodadvances.2023010805.

Menssen AJ, Hudson CA, Alonzo T, Gerbing R, Pardo L, Leonti A, Cook JA, Hsu F, Lott LL, Dai F, Fearing C, Ghirardelli K, Hylkema T, Tarlock K, Loeb KR, Kolb EA, Cooper T, Pollard J, Wells DA, Loken MR, Aplenc R, Meshinchi S, Eidenschink Brodersen L: CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group. Haematologica Feb 2024 Notes: doi: 10.3324/haematol.2023.283757.

Myers RM, Devine KJ, Li Y, Lawrence S, Barz Leahy A, Liu H, Vernau L, Callahan C, Baniewicz D, Kadauke S, McGuire R, Wertheim G, Kulikovskaya I, Gonzales V, Fraietta JA, DiNofia A, Hunger SP, Rheingold SR, Aplenc R, June CH, Grupp SA, Wray L, Maude SL: Reinfusion of CD19 CAR T Cells for Relapse Prevention and Treatment in Children with Acute Lymphoblastic Leukemia. Blood Adv Feb 2024 Notes: doi: 10.1182/bloodadvances.2024012885.

Tarlock K, Gerbing RB, Ries RE, Smith JL, Leonti AR, Huang BJ, Kirkey DC, Robinson L, Peplinski JH, Lange B, Cooper TM, Gamis AS, Kolb EA, Aplenc R, Pollard JA, Meshinchi S: Prognostic Impact of Co-occurring Mutations in FLT3-ITD Pediatric Acute Myeloid Leukemia. Blood Adv Jan 2024 Notes: doi: 10.1182/bloodadvances.2023011980.

Shastri VM, Chauhan L, Gbadamosi M, Alonzo TA, Wang Y, Aplenc R, Hirsch BA, Kolb EA, Gamis AS, Meshinchi S, Lamba JK: Genetic variation in DNA damage response pathway and response to Gemtuzumab Ozogamicin in pediatric AML: a report from the Children's Oncology Group. Clin Cancer Res Jan 2024 Notes: doi: 10.1158/1078-0432.CCR-23-2073.

Winestone LE, Getz KD, Li Y, Burrows E, Scheurer ME, Tam V, Gramatges MM, Wilkes JJ, Miller TP, Seif AE, Rabin KR, Fisher BT, Aplenc R: Racial and ethnic disparities in acuity of presentation among children with newly diagnosed acute leukemia. Pediatr Blood Cancer 71(1), Jan 2024 Notes: doi: 10.1002/pbc.30726.

Oganisian A, Getz KD, Alonzo TA, Aplenc R, Roy JA: Bayesian semiparametric model for sequential treatment decisions with informative timing. Biostatistics Jan 2024 Notes: doi: 10.1093/biostatistics/kxad035.

back to top
Last updated: 03/21/2024
The Trustees of the University of Pennsylvania